When John Buse, one of the America’s leading diabetologists, agreed to speak with a journalist about Exubera, Pfizer’s inhaled insulin, he had no idea that he would find himself in the crosshairs of angry bloggers.
But that’s what happens when you’re the president-elect of the American Diabetes Association.
As Kelly pointed out in her recent blog for Revolution Health, (www.revolutionhealth.com/blogs/kellyclose), Buse is getting a quick education on the “diabetic furies:” the passions run deep with this disease, and his words now have a significant echo effect. In this instance, he criticized Exubera (“there is no advantage to [it], and there may be a significant safety risk”), and his comments drew stinging rebukes for online commentators – hardly the response he would have expected from the very people to whom he’s devoted his career.
Buse is one of our favorite clinicians and researchers, and he knows he now needs to be careful in his choice of words – but we hope he doesn’t become timid. We need him to rattle a few cages.
Please check out the Revolution Health link to read the entire blog.